日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

AS01(B)-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a post-hoc cross-protocol comparison of results from HVTN 100, 107, 120, and 702

AS01(B)-、MF59-和铝佐剂与HIV疫苗免疫原性:HVTN 100、107、120和702试验结果的事后交叉方案比较

Menezes, Ferdinando; Chen, Shiyu; Grunenberg, Nicole; Malahleha, Mookho; Mngadi, Kathy; Muyoyeta, Monde; Laher, Fatima; Chirenje, Zvavahera Mike; Bekker, Linda-Gail; Goepfert, Paul; Gray, Glenda E; Tomaras, Georgia; McElrath, M Juliana; Kallas, Esper; Roxby, Alison C; Moodie, Zoe

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost

与腺病毒启动和三聚体gp140蛋白增强相比,ALVAC启动和单体gp120蛋白增强可诱导不同的HIV-1特异性体液和细胞免疫反应。

Fisher, Leigh H; Lazarus, Erica; Yu, Chenchen; Moodie, Zoe; Stieh, Daniel J; Yates, Nicole; Zhang, Lu; Sawant, Sheetal; De Rosa, Stephen C; Cohen, Kristen W; Morris, Daryl; Grant, Shannon; Randhawa, April; Miner, Maurine D; Hendriks, Jenny; Wegmann, Frank; Gill, Katherine M; Laher, Fatima; Bekker, Linda-Gail; Gray, Glenda E; Corey, Lawrence; McElrath, M Juliana; Martin, Troy; Gilbert, Peter B; Tomaras, Georgia; Walsh, Stephen R; Baden, Lindsey R

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

在13项HIV疫苗试验中,采用多价DNA启动疫苗联合匹配的多价蛋白/GLA-SE加强免疫方案,诱导出了最强效、最广泛的IgG和IgG3 V1V2结合抗体以及CD4+ T细胞反应。

Moodie, Zoe; Li, Shuying Sue; Giorgi, Elena E; Williams, LaTonya D; Dintwe, One; Carpp, Lindsay N; Chen, Shiyu; Seaton, Kelly E; Sawant, Sheetal S; Zhang, Lu; Heptinstall, Jack; Liu, Shuying; Grunenberg, Nicole; Tomaka, Frank; Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Ake, Julie A; Vasan, Sandhya; Pantaleo, Giuseppe; Frank, Ian; Baden, Lindsey R; Goepfert, Paul A; Keefer, Michael; Chirenje, Mike; Hosseinipour, Mina C; Mngadi, Kathryn; Laher, Fatima; Garrett, Nigel; Bekker, Linda-Gail; De Rosa, Stephen; Andersen-Nissen, Erica; Kublin, James G; Lu, Shan; Gilbert, Peter B; Gray, Glenda E; Corey, Lawrence; McElrath, M Juliana; Tomaras, Georgia D

Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines

对ALVAC-HIV和二价C亚型gp120/MF59 HIV疫苗的性别差异免疫反应进行回顾性分析

Ackerley, Cassie G; Edupuganti, Srilatha; Yu, Chenchen; Roxby, Alison C; Seaton, Kelly E; Bekker, Linda-Gail; Allen, Mary; DeRosa, Stephen C; Yates, Nicole L; Heptinstall, Jack; Mkhize, Nonhlanhla N; Malahleha, Mookho; Mngadi, Kathryn; Daniels, Brodie; Innes, Craig; Furch, Briana D; Koutsoukos, Marguerite; Ferrari, Guido; Morris, Lynn; Montefiori, David C; McElrath, M Juliana; Tomaras, Georgia D; Laher, Fatima; Moodie, Zoe

Deciphering HIV vaccine-induced antibody response according to ethnicity

根据种族解读艾滋病疫苗诱导的抗体反应

Lin, Li-Yun; Ferte, Thomas; Chachage, Mkunde; Casteano, Celso; Laumond, Géraldine; Schmidt, Sylvie; Tahar, Ouria; Carapito, Raphael; Bekker, Linda-Gail; Churchyard, Gavin; Keefer, Michael; Moodie, Zoe; Viegas, Edna; Geldmacher, Christof; Lhomme, Edouard; Moog, Christiane

High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)

在一项 1 期随机、开放标签临床试验 (HVTN 302) 中,接受 HIV-1 BG505 MD39.3 三聚体 mRNA 研究疫苗后出现慢性荨麻疹的频率较高

Riddler, Sharon A; Moodie, Zoe; Clark, Jesse; Yen, Catherine; Allen, Mary; Furch, Briana D; Lu, Huiyin; Grant, Shannon; Mondal, Kajari; Anderson, Maija; Maenza, Janine; Lemos, Maria P; Woodward Davis, Amanda S; Walsh, Stephen R; Sobieszczyk, Magdalena E; Frank, Ian; Goepfert, Paul; Stephenson, Kathryn E; Baden, Lindsey R; Tieu, Hong-Van; Keefer, Michael C; McElrath, M Juliana; Kublin, James G; Corey, Lawrence

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial

在一项 I 期临床试验中,接种 mRNA 编码的膜锚定 HIV 包膜三聚体疫苗可诱导产生 2 级中和抗体。

Parks, K Rachael; Moodie, Zoe; Allen, Mary A; Yen, Catherine; Furch, Briana D; MacPhee, Kellie J; Ozorowski, Gabriel; Heptinstall, Jack; Hahn, William O; Zheng, Zihan; Lu, Huiyin; Grant, Shannon; Domin, Elize; Duff, Michael O; Seese, Aaron; Marini-Macouzet, Constanza; Ballweber-Fleming, Lamar; Lee, Wen-Hsin; Cottrell, Christopher A; Liguori, Alessia; Georgeson, Erik; Alavi, Nushin; Kubitz, Michael; Phelps, Nicole; Seaton, Kelly E; Cohen, Kristen W; Anderson, Maija A; Mondal, Kajari; Laufer, Dagna S; Kublin, James G; Ward, Andrew B; Hyrien, Ollivier; De Rosa, Stephen C; Himansu, Sunny; Leav, Brett; Reuter, Caroline; Tomaras, Georgia D; Montefiori, David; Walsh, Stephen R; Frank, Ian; Sobieszczyk, Magdalena E; Goepfert, Paul A; Stephenson, Kathryn E; Baden, Lindsey R; Van Tieu, Hong; Keefer, Michael C; Clark, Jesse; Riddler, Sharon A; Schief, William R; McElrath, M Juliana

Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses

性别而非种族和地理出身对疫苗诱导的HIV特异性抗体反应有影响

Mbuya, Wilbert; Horvath, Augusta; Held, Kathrin; Maganga, Lucas; Hoelscher, Michael; Bekker, Linda-Gail; Duerr, Ann; Moodie, Zoe; Churchyard, Gavin; Keefer, Michael C; Viegas, Edna; Moog, Christiane; Geldmacher, Christof; Chachage, Mkunde

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

在未感染 HIV 的健康成人中,采用 C 亚型 ALVAC-HIV (vCP2438) 疫苗初免联合二价 C 亚型 gp120 疫苗加强免疫(佐剂为 MF59 或明矾)的安全性和免疫原性:一项 1/2a 期随机试验 (HVTN 107)

Moodie, Zoe; Andersen-Nissen, Erica; Grunenberg, Nicole; Dintwe, One B; Omar, Faatima Laher; Kee, Jia J; Bekker, Linda-Gail; Laher, Fatima; Naicker, Nivashnee; Jani, Ilesh; Mgodi, Nyaradzo M; Hunidzarira, Portia; Sebe, Modulakgota; Miner, Maurine D; Polakowski, Laura; Ramirez, Shelly; Nebergall, Michelle; Takuva, Simbarashe; Sikhosana, Lerato; Heptinstall, Jack; Seaton, Kelly E; De Rosa, Stephen; Diazgranados, Carlos A; Koutsoukos, Marguerite; Van Der Meeren, Olivier; Barnett, Susan W; Kanesa-Thasan, Niranjan; Kublin, James G; Tomaras, Georgia D; McElrath, M Juliana; Corey, Lawrence; Mngadi, Kathryn; Goepfert, Paul

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial

在接种C亚型ALVAC-HIV (vCP2438)疫苗初免后,再接种二价C亚型gp120/MF59疫苗加强针(HVTN 100)30个月后的安全性和免疫原性:一项1/2期随机双盲安慰剂对照试验

Naicker, Vimla; Laher, Fatima; Bekker, Linda-Gail; Seaton, Kelly E; Allen, Mary; De Rosa, Stephen; Yates, Nicole L; Mkhize, Nonhlanhla N; Saunders, Kevin; Heptinstall, Jack; Malahleha, Mookho; Mngadi, Kathryn; Daniels, Brodie; Innes, Craig; Yu, Chenchen; Modise, Tandile; Bekker, Valerie; Grunenberg, Nicole; Furch, Briana; Miner, Maurine D; Phogat, Sanjay; Diazgranados, Carlos A; Gurunathan, Sanjay; Koutsoukos, Marguerite; Van Der Meeren, Olivier; Roxby, Alison C; Ferrari, Guido; Morris, Lynn; Montefiori, David; McElrath, M Juliana; Tomaras, Georgia D; Moodie, Zoe